1,769
Views
37
CrossRef citations to date
0
Altmetric
Review

Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature

ORCID Icon, &
Pages 53-58 | Received 01 Nov 2020, Accepted 18 Nov 2020, Published online: 02 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Hui Li, Lu Xie, Hongdi Yao, Lexing Zhang, Sanhong Liang & Wen Lyu. (2022) Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn’s Disease. International Medical Case Reports Journal 15, pages 117-124.
Read now
Shana Rakowsky, Konstantinos Papamichael & Adam S. Cheifetz. (2022) Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 16:3, pages 235-249.
Read now

Articles from other publishers (35)

Arafa Djalal, Serre-Yu Wong, Jean-Frédéric Colombel, Ryan Ungaro & Maia Kayal. (2024) Problem with Hookups: Perianal Fistula After Ileal Pouch-Anal Anastomosis. Digestive Diseases and Sciences 69:4, pages 1102-1104.
Crossref
Manish Manrai, Atul Abhishek Jha, Saurabh Dawra & Aditya Vikram Pachisia. (2024) Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future. Future Pharmacology 4:1, pages 279-316.
Crossref
Tina Nie. (2024) Treating paediatric Crohn’s disease is challenging but new treatments hold promise. Drugs & Therapy Perspectives 40:3, pages 121-126.
Crossref
Malcolm Irani & Bincy Abraham. (2024) Choosing Therapy for Moderate to Severe Crohn’s Disease. Journal of the Canadian Association of Gastroenterology 7:1, pages 1-8.
Crossref
Jalpa Devi, David H. Ballard, Tina Aswani-Omprakash, Alyssa M. Parian & Parakkal Deepak. (2024) Perianal fistulizing Crohn’s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies. Indian Journal of Gastroenterology 43:1, pages 48-63.
Crossref
Adrià Quesada-Simó, Francisco Giner, Lucas Barea-Moya, Alejandro Garrido-Marin, Alejandro Mínguez, Pilar Nos & Sara Gil-Perotín. (2024) Anti-CD20-Triggered Crohn’s-Like Disease with Severe Perianal Involvement in a Patient with Multiple Sclerosis: Case Report, Review of the Literature, and Potential Therapeutic Approach. Sclerosis 2:1, pages 7-12.
Crossref
Shannon ChangMegan MurphyLisa Malter. (2024) A Review of Available Medical Therapies to Treat Moderate-to-Severe Inflammatory Bowel Disease. American Journal of Gastroenterology 119:1, pages 55-80.
Crossref
Leticia ROSEVICS, Mariane Cristina SAVIO, Emilton LIMA JÚNIOR & Odery RAMOS JÚNIOR. (2023) FISTULIZING PERIANAL CROHN’S DISEASE: IS THE PATIENT’S SEX A BURDEN? A SYSTEMATIC REVIEW. Arquivos de Gastroenterologia 60:4, pages 490-524.
Crossref
Julie Gallagher, Joel R. Rosh & Benjamin Sahn. (2023) The Future of Advanced Therapies for Pediatric Crohn’s Disease. Pediatric Drugs 25:6, pages 621-633.
Crossref
C.E. Alcántara-Figueroa, E.F. Coronado-Rivera, E.F. Estela-Vásquez, D.C. Calderón-Cabrera & R.A. Alcántara-Ascón. (2023) Ustekinumab and remission in perianal Crohn's disease: A case report. Revista de Gastroenterología de México (English Edition) 88:4, pages 431-432.
Crossref
C.E. Alcántara-Figueroa, E.F. Coronado-Rivera, E.F. Estela-Vásquez, D.C. Calderón-Cabrera & R.A. Alcántara-Ascón. (2023) Ustekinumab y remisión en enfermedad de Crohn con compromiso perianal: reporte de un caso. Revista de Gastroenterología de México 88:4, pages 431-432.
Crossref
Marleen Bouhuys, Paola Mian & Patrick F. van Rheenen. (2023) Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use. Frontiers in Pharmacology 14.
Crossref
Arshdeep Singh, Vandana Midha, Gursimran Singh Kochhar, Bo Shen & Ajit Sood. (2023) Management of Perianal Fistulizing Crohn’s Disease. Inflammatory Bowel Diseases.
Crossref
Alyssa M. ParianMegan ObiPhillip FleshnerDavid A. Schwartz. (2023) Management of Perianal Crohn's Disease. American Journal of Gastroenterology 118:8, pages 1323-1331.
Crossref
John Gubatan, Spencer Frost, Steven Levitte & Kian Keyashian. (2023) Rates and Predictors of Long-term Clinical Outcomes in Patients With Perianal Crohn’s Disease on Biologic Therapy. Journal of Clinical Gastroenterology 57:6, pages 617-623.
Crossref
Siyan Cao, Marco Colonna & Parakkal Deepak. (2023) Pathogenesis of Perianal Fistulising Crohn’s Disease: Current Knowledge, Gaps in Understanding, and Future Research Directions. Journal of Crohn's and Colitis 17:6, pages 1010-1022.
Crossref
M. V. Shapina. (2023) Theoretical aspects of prescribing ustekinumab as first-line therapy for Crohn’s disease. Meditsinskiy sovet = Medical Council:8, pages 175-180.
Crossref
Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab & Reza Malekzadeh. (2023) Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases. Middle East Journal of Digestive Diseases 15:2, pages 83-106.
Crossref
Mohammad Shehab, Fatema Alrashed, Valérie Heron, Sophie Restellini & Talat Bessissow. (2023) Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn’s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Inflammatory Bowel Diseases 29:3, pages 367-375.
Crossref
Rui Li. (2023) Approaches in the treatment of perianal fistula in Crohn disease. Journal of Coloproctology 43:01, pages 043-048.
Crossref
Jiayin Yao, Heng Zhang, Tao Su, Xiang Peng, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhi & Min Zhang. (2023) Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis. Journal of Clinical Medicine 12:3, pages 939.
Crossref
Naoto Saigusa & Jun-ichi Saigusa. (2023) Fistula Remission 8 Weeks after Induction of Biologics is an Independent Influencing Factor for Long-term Prognosis in Bio Naïve Patients with Crohn's Perianal Fistulasクローン病合併痔瘻において生物製剤導入後8週目の寛解が長期予後の予測因子である. Nippon Daicho Komonbyo Gakkai Zasshi 76:6, pages 426-431.
Crossref
Kira L. Newman, Laura A. Johnson, Ryan W. Stidham & Peter D. R. Higgins. (2023) Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease. Therapeutic Advances in Gastroenterology 16, pages 175628482211482.
Crossref
Fabian Juliao-Baños, Laura Osorio, Jhon Carvajal, Gabriel Mosquera-Klinger, Anwar Medellín, Jorge Padrón, Belén de Molano, Fabián Puentes, Edwin Muñoz, Gustavo Reyes, Fabio Gil, Viviana Parra-Izquierdo & Héctor Sánchez. (2022) Características clínicas y tratamiento de la enfermedad de Crohn perianal fistulizante en Colombia: resultados de un registro multicéntrico. Gastroenterología y Hepatología 45:9, pages 690-696.
Crossref
Fabian Juliao-Baños, Laura Osorio, Jhon Carvajal, Gabriel Mosquera-Klinger, Anwar Medellín, Jorge Padrón, Belén de Molano, Fabián Puentes, Edwin Muñoz, Gustavo Reyes, Fabio Gil, Viviana Parra-Izquierdo & Héctor Sánchez. (2022) Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry. Gastroenterología y Hepatología (English Edition) 45:9, pages 690-696.
Crossref
Jeroen Geldof, Nusrat Iqbal, Jean-Frédéric LeBlanc, Sulak Anandabaskaran, Rachel Sawyer, Christianne Buskens, Willem Bemelman, Krisztina Gecse, Lilli Lundby, Amy L Lightner, Silvio Danese, Antonino Spinelli, Michele Carvello, Omar Faiz, Janindra Warusavitarne, Phillip Lung, Danny De Looze, André D'Hoore, Séverine Vermeire, Ailsa Hart & Phil Tozer. (2022) Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. The Lancet Gastroenterology & Hepatology 7:6, pages 576-584.
Crossref
Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn & Peter Laszlo Lakatos. (2022) The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials. Journal of Clinical Medicine 11:11, pages 3045.
Crossref
Ferdinando D’Amico, Laurent Peyrin-Biroulet & Silvio Danese. (2022) Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm. Journal of Crohn's and Colitis 16:Supplement_2, pages ii30-ii41.
Crossref
Mir Zulqarnain, Parakkal Deepak & Andres J. Yarur. (2022) Therapeutic Drug Monitoring in Perianal Fistulizing Crohn’s Disease. Journal of Clinical Medicine 11:7, pages 1813.
Crossref
Gustavo Drügg Hahn, Petra Anna Golovics, Panu Wetwittayakhlang, Alex Al Khoury, Talat Bessissow & Peter Laszlo Lakatos. (2022) Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?. Biomedicines 10:4, pages 749.
Crossref
Christian Schineis, Johannes C. Lauscher, M. E. Kreis, Katharina Beyer & Benjamin Weixler. (2021) Flap-Techniken – heute noch „State of the Art“?Flap techniques—still state of the art today?. coloproctology 44:1, pages 17-22.
Crossref
Clare Yzet, Franck Brazier, Charles Sabbagh & Mathurin Fumery. (2022) Managing complex perianal disease after anti-TNF failure: Where to go next?. Current Research in Pharmacology and Drug Discovery 3, pages 100081.
Crossref
Gala M Godoy Brewer, George Salem, Muhammad A Afzal, Berkeley N Limketkai, Zadid Haq, Maryam Tajamal, Joanna Melia, Mark Lazarev, Florin M Selaru & Alyssa M. Parian. (2021) Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis. BMJ Open Gastroenterology 8:1, pages e000702.
Crossref
Abhinav Vasudevan, David H Bruining, Edward V Loftus, William Faubion, Eric C Ehman & Laura Raffals. (2021) Approach to medical therapy in perianal Crohn’s disease. World Journal of Gastroenterology 27:25, pages 3693-3704.
Crossref
Joana Revés, Ryan C. Ungaro & Joana Torres. (2021) Unmet needs in inflammatory bowel disease. Current Research in Pharmacology and Drug Discovery 2, pages 100070.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.